Atomoksetin kullanımında nadir bir yan etki: Hemolitik anemi

İlaca bağlı otoimmun hemolitik anemi, eritrosit membranı ve immun sistem arasındaki etkileşim sonucu ortaya çıkan, eritrosit yüzey antijenlerine bağlanan antikorların indüklediği ve eritrosit yıkımı ile karakterize immunolojik bir durum olup çocuklarda nadir olarak görülmektedir. Yaklaşık 130 ilacın hemolitik anemiye neden olduğuna ilişkin yeterli kanıt vardır. Psikotrop ilaçlara bağlı hematolojik yan etkiler nadir olup literatürde atomoksetin kullanımı ile hemolitik anemi gelişen olguya rastlanmamıştır. Bu nedenle bu olgu sunumunun literatüre ve olası düzeneklere katkı sağlayacağı düşünüldüğünden sunulmaya değer bulunmuştur.

An unusual side effect by atomoxetin use: hemolytic anemia

Drug-induced autoimmune hemolytic anemia, inducing by antibodies that bind to the erythrocyte surface antigen and resulting by interaction between the immune system and red blood cell membrane, an immunological status characterized by erythrocyte destruction is rare in children. There is enough evidence that about 130 drug caused hemolytic anemia. Hematological side effects due to psychotropic drugs is rare and in the literature there is no case developing hemolytic anemia with the use of atomoxetine. Therefore, this case report is found worthy to be presented and expected to contribute to the literature and possible mechanisms.

PDF

___

1. Garratty G. Review: drug-induced immune hemolytic anemia--the last decade. Immunohematology/American Red Cross 2004; 20(3):138.

2. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002; 69(4):258-271.

3. Garratty G. Immune hemolytic anemia associated with drug thera py. Blood Rev 2010; 24(4):143- 150. 4. Chaudhry MM, Abrar M, Mutahir K, Mendoza C. Oxcarbazepine-induced hemolytic anemia in a geriatric patient. Am J Ther 2008; 15(2):187-189.

5. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/ hyperactivity disorder. Clini Ther 2003; 25(12):3065-3083.

6. Garratty G. Immune cytopenia associated with antibiotics. Transfus Med Rev 1993;7(4):255-267.

7. Citak A, Garratty G, Ücsel R, Karabocuoglu M, Uzel N. Ceftriaxone-induced haemolytic anaemia in a child with no immune deficiency or haematological disease. J Paediatr Child Health 2002; 38(2):209-210.

8. Salama A, Mueller-Eckhardt C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. New Engl J Med 1985; 313(8):469-474.

9. Kirtland III HH, Mohler DN, Horwitz DA. Methyldopa inhibition of suppressor-lymphocyte function: a proposed cause of autoimmune hemolytic anemia. New Engl J Med 1980; 302(15):825-832.

10. Oyesanmi O, Kunkel EJ, Monti DA, Field HL. Hematologic side effects of psychotropics. Psychosomatics 1999; 40(5):414-421.

11. Lindberg L, Norden A. Severe hemolytic reaction to chlorpromazine. Acta Med Scand 1961; 170(2):195-199.

12. Stockwell DC, Bell MJ, Wong EC, Luban NL. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin sc disease (hbsc): 640. Crit Care Med 2004; 32(12):A180.

13. Özkan AS. Seftriaksona bağlı hemolitik anemi: Olgu sunumu. Van Tıp Dergisi 2014; 21(3):174- 176.